Maze Therapeutics (NASDAQ:MAZE) Shares Down 6.8% – Time to Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price dropped 6.8% during trading on Monday . The company traded as low as $26.42 and last traded at $26.71. 388,599 shares were traded during trading, a decline of 42% from the average session volume of 669,093 shares. The stock had previously closed at $28.65.

Analysts Set New Price Targets

A number of equities analysts have issued reports on MAZE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Truist Financial decreased their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Trading Down 6.4%

The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -10.60 and a beta of 2.22. The company has a fifty day moving average of $27.54 and a 200-day moving average of $33.56.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. As a group, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer directly owned 23,337 shares in the company, valued at approximately $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This represents a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 141,470 shares of company stock worth $3,902,714. 5.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its position in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics in the 4th quarter valued at about $39,000. Ameritas Investment Partners Inc. raised its holdings in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the 4th quarter worth approximately $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the 2nd quarter worth approximately $48,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.